The global basal cell nevus syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Basal cell nevus syndrome is a genetic disorder that usually leads to eye related problems, skin lesions, and other issues. It is also known by the name, Beckwith-Wiedemann syndrome or Gorlin's syndrome. Basal cell nevus syndrome is caused by changes in a tumor suppressor gene, called PTCH1. This gene is located on chromosome 9. Mutations in this gene may increase the risk of some cancers. Molecular genetic testing of PTCH1 is available on a clinical basis. A few of the patients with basal cell nevus syndrome may experience seizures in both infancy and adulthood due to the mutation of an enzyme that regulates sugar uptake. Therefore, as a treatment measure to control this medical condition, the global basal cell nevus syndrome drug market is anticipated to grow significantly in the future years. 

Adding to this, the growing awareness for skin diseases, the introduction of new drugs in the market, and rising demand for dermatological products are some factors expected to fuel the market growth. As a matter of fact, the risk for ovarian tumors and skin cancer gets multiplied in patients suffering from basal cell nevus syndrome (also called Gorlin syndrome or nevoid basal cell carcinoma), a rare autosomal dominant cancer genetic syndrome. Thus, to avoid the further complications of the syndrome, the demand for basal cell nevus syndrome drugs is likely to see a major boost in the future years.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Adgero Biopharmaceuticals Holdings, Inc., and Mayne Pharma Group Ltd., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Basal Cell Nevus Syndrome Drug Market Report by Segment

By Type

• Itraconazole
• Patidegib Hydrochloride
• REM-001
• TG-1042
• Trifarotene
• Others

By Application

• Hospital
• Clinic
• Others

Global Basal Cell Nevus Syndrome Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa